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The number needed to treat (NNT) is a benchmark
invented in evidence-based medicine to describe the incre-
mental effect between two medical treatments. Although
it is potentially useful on pharmacoeconomics, the 
estimate is limited to be valid at a certain endpoint of a
clinical trial. OBJECTIVE: To overcome such time-
constraint, we developed a new method that can stan-
dardize the NNT to ex/intrapolate over the time axis.
METHOD: We reviewed a linear approximation model
in which the absolute risk reduction (ARR), the recipro-
cal of the NNT, is directly proportional to the duration
of the clinical trial. Then, we extended the linear model
into a more complex model using exponential function to
ex/interpolate the NNT, and also developed mathemati-
cally how to calculate the incremental cost-effectiveness
ratio according to the standardized NNT. RESULTS: We
found the linear model has a fatal disadvantage that the
time-adjusted ARR can be larger than 1 (i.e., the time-
adjusted NNT can become impractically smaller than 1)
under the assumption of constant relative risk reduction
and constant event rate over time. On the other hand, the
exponential model was able to overcome such a disad-
vantage in consistency with practical assumptions. CON-
CLUSION: The exponential model is practically better
than linear model to standardize the NNT. The method
we developed is applicable to estimate the incremental
cost-effectiveness introducing the ratio of incremental
cost per person responded to a treatment.
PMD2
THE USE OF DISCRETE CHOICE MODELLING
IN THE DESIGN OF CLINICAL TRIALS
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OBJECTIVE: Discrete choice modelling (DCM) applied
to data generated by stated preference (SP) experiments
is being used increasingly by health economists as a
method for valuing process and outcome characteristics
of health interventions in utility or monetary terms. The
purpose of this paper is to illustrate how sponsors of ran-
domised controlled trials (RCTs) could use DCM to assist
with the planning of their studies. The approach is 
illustrated using a case study of the design of trials to 
evaluate the use of adjuvant bisphosphonates in the 
management of patients with primary operable breast
cancer. METHODS: A stated preference experiment was
conducted amongst UK specialists involved in the 
management of patients with primary operable breast
cancer. Respondents were asked to choose 1 bisphospho-
nate regimen from each of 16 binary choice scenarios.
Each regimen was characterised in terms of the following
trial design attributes: 1) Primary endpoint; 2) Effect size
demonstrated; 3) Uncertainty surrounding demonstrated
effect; 4) Duration of observation; 5) Study population;
and 6) Cost of the treatment alternatives. The survey was 
performed using a telephone-mail-telephone approach.
Probit analysis was used to estimate a binary choice
model of drug prescribing behaviour. RESULTS: 54 
specialists fully completed the survey questionnaire 
providing a sample of 864 discrete choice responses. In
qualitative terms, the signs on the coefﬁcients were in line
with prior expectations and all coefﬁcients were statisti-
cally signiﬁcant at conventional levels. The marginal and
average effects were used to determine the relative impor-
tance of the attributes and to rank alternative designs in
terms of the ex ante probabilities of product adoption.
CONCLUSIONS: DCM could be used by sponsors of
RCTs to incorporate decision-maker preferences into
their designs. It could also be used to estimate product
uptake contingent upon different designs. Results from
this study suggest that the approach is both feasible and
valid.
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OBJECTIVES: Patient satisfaction is a multi-facet 
construct and an important parameter of patient 
reported outcomes (PRO). In order to be able to measure
chronic pain patient’s satisfaction, the relevance of dif-
ferent dimensions were identiﬁed, with a focus on the role
of analgesic medication. METHOD: First, a literature
review was conducted to summarise the current instru-
ments of PRO measures. To identify relevant dimensions
of patient’s satisfaction, 4 focus groups were held (10
patients with tumour pain, 10 with non-tumour pain). 
In semi-standardised interviews, patients’ personal pain
experience and articulation were explored, including their
satisfaction with analgesics in different dosage forms
(oral, transdermal). RESULTS: Besides HRQoL and other
parameters, the PRO referred to the literature also include
a reference to the importance of data relating to patient
satisfaction. To date, instruments used to survey patient
satisfaction have three dimensions: 1) Satisfaction with
